Performance evaluation study of ID RHD XT, a new genotyping assay for the detection of high‐prevalence RhD negative and weak D types-Reference-Cited by-同舟云学术

Performance evaluation study of ID RHD XT, a new genotyping assay for the detection of high‐prevalence RhD negative and weak D types

Published:2018-08-19 Issue:7 Volume:113 Page:694-700
ISSN:0042-9007
Container-title:Vox Sanguinis
language:en
Short-container-title:Vox Sang

Author:

Molano Araitz¹,Apraiz Izaskun¹,España Patricia¹,Azkarate Maria²,Vesga Miguel Ángel²,Rubia Montserrat²,Piedrabuena Mercedes²,Puente Fernando³,Veldhuisen Barbera⁴,Schoot Ellen⁴,Tejedor Diego¹,López Mónica¹

Affiliation:

1. R&D Area Progenika Biopharma A Grifols Company Derio Spain

2. Centro Vasco de Transfusiones y Tejidos Humanos Galdakao Spain

3. Banco de Sangre y Tejidos de Aragón Zaragoza Spain

4. Sanquin Blood Supply Research Amsterdam the Netherlands

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vox.12701

Reference29 articles.

1. WesthoffC:Guidelines for Naming RH Alleles. Available at:http://www.isbtweb.org/fileadmin/user_upload/files-2015/red%20cells/blood%20group%20allele%20terminology/Guidelines%20Naming%20RH%20Alleles%20v2.0%20110914.pdf. [Last accessed 25 January 2018].2012

2. Human Blood Groups

3. Policies and Procedures Related to Testing for Weak D Phenotypes and Administration of Rh Immune Globulin: Results and Recommendations Related to Supplemental Questions in the Comprehensive Transfusion Medicine Survey of the College of American Pathologists

4. It's time to phase inRHDgenotyping for patients with a serologic weak D phenotype

5. Molecular Basis of Weak D Phenotypes

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accuracy of Blood Group Typing in the Management and Prevention of Alloimmunization;Human Blood Group Systems and Haemoglobinopathies;2021-02-17

2. A multi‐centre study on the performance of the molecular genotyping platform ID RHD XT for resolving serological weak RhD phenotype in routine clinical practice;Vox Sanguinis;2020-04

3. It's time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4;Transfusion;2020-03-12